HOME >> BIOLOGY >> NEWS
UF Researcher Designs Pill To Control Mosquitoes

ecause they were not digesting, so then we knew we had a diet pill, not a birth control pill.

"Fortunately, now we can synthesize the hormone, so we don't have to use 100,000 ovaries for each batch anymore," Borovsky said.

The synthesized hormone is inexpensive, as is chlorella, which is found and produced worldwide. Chlorella, in fact, turns out to be the perfect ride for the mosquito hormone, because it can be freeze-dried and stored for long periods and then brought back to life as the deadly diet pill.

The mosquito fen-phen is benign environmentally. Unlike DDT and some other pesticides, it does not alter the environment in any way, except for poisoning the larval lunch. Mosquitoes that feed on the hormone-laced chlorella starve to death within 72 hours.

"This is a natural bullet that we can use in the environment because the hormone doesn't stay in the environment," Borovsky said. "The chlorella stops producing the hormone within three weeks."

That's by design, Borovsky said. If the hormone were incorporated into the chlorella genome and chlorella continued to produce the hormone, making it omnipresent in the environment, mosquitoes could become resistant to it. But the hormone sits outside the genome, and after the third division of the chlorella it no longer can be detected.

Of course, Borovsky points out, if mosquitoes become resistant to their own reproductive hormone that could have unknown adverse consequences for them as well.

"We have to stay a step ahead of them or outsmart them all over again," Borovsky said.

In the decade since he began work on the pill, Borovsky has made believers out of even the most ardent doubters.

"Ten years ago, everybody was laughing at us, but now they are taking us seriously," Borovsky said. "Eight years ago, at a Vancouver meeting, a colleague harshly criticized this work. He just did not believe it."

The next step, Borovsky says, is to develop diet pills for infamous agricultural pests. Curren
'"/>

Contact: Cindy Spence
crsp@gnv.ifas.ufl.edu
352-392-1773
University of Florida
2-Dec-1997


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Researcher Designs Pill Control Mosquitoes

(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: